ReviewNeurosurgery practice2025
Departments of Neurosurgery are Leaders in Highly Cited Glioblastoma Research.
Review in Neurosurgery practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
objectivesWe conducted a bibliometric analysis of highly cited glioblastoma (GBM) research published between 2013 and 2023, focusing on identifying key academic departments and institutional contributions within the United States.
methodsA comprehensive search of the Web of Science database was performed to identify "highly cited articles," defined as those receiving the top one percent for citations within their field each year. Primary research articles authored by researchers at U.S. institutions between 2013 and 2023 were included. We categorized articles by subject area and departmental contributions and used VOSviewer and R for data visualization and analysis.
resultsOverall, 169 highly cited GBM articles were included in the study. Neurosurgery emerged as the largest contributing department type, accounting for 28.4% (48/169) of highly cited articles. This was followed by departments of biology or genetics (22/169), neurology or neuro-oncology (16/169), and radiology or radiation oncology (13/169). "Immunology and Immunotherapy" was the dominant subject area for highly cited papers, with 50.3% (85/169) investigating the immunological landscape of GBM or using immunotherapy as the primary treatment modality. Keyword analysis demonstrated a thematic shift toward tumor biology and immune-based therapies over the study period, highlighting emerging trends in GBM research.
conclusionDepartments of neurosurgery have established themselves as key drivers in GBM research. The prominence of tumor biology and immunotherapy reflect broader shifts in treatment approaches. Continued support for neurosurgical departments and targeted funding initiatives is essential for advancing GBM research, fostering innovation, and improving patient outcomes in this challenging field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.